Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Klövern on its offer for Agora
Mandate

Vinge advises Klövern on its offer for Agora

October 09, 2018 Capital Markets and Public M&A

Klövern AB (publ) has, through its indirectly wholly-owned subsidiary Dagon Sverige AB, made a public cash offer to the shareholders of A Group Of Retail Assets Sweden AB (publ) (Nasdaq First North).

Klövern is a listed real estate company committed with closeness and commitment to offering attractive commercial premises, and developing housing, in growth regions. The public offer entails that the shareholders in Agora are offered a cash consideration of SEK 30.00 for each class A and class B share and SEK 275.00 for each preference share in Agora. The offer implies a value of MSEK 1,023 for all shares in Agora.

Vinge advises Klövern.  The Vinge team is headed by Dain Hård Nevonen and also includes Rikard Lindahl, Malte Hedlund and Anna-Karin Alin, as well as Grant McKelvey and Alva Hägglund (on competition matters).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026